Why Echocardiography Cannot Diagnose Pulmonary Hypertension

First, PDE5 inhibition, to promote vascular relaxation via the cGMP pathway. Second, soluble guanylate cyclase stimulation, to address back-pressure and encourage vasodilation. Third, endothelin receptor blockade, to retard smooth muscle cell hypertrophy and reduce pulmonary vascular resistance. Sotatercept adds a fourth, distinct pathway — anti-proliferative inhibition of activin signalling — which addresses the underlying vascular remodelling rather than just haemodynamics.

The right ventricle is a volume-handling ventricle, not designed for pressure overload — you can load it with considerable volume and it won't fail, because volume is its domain. But impose a pressure overload, as in pulmonary hypertension, and it hypertrophies to compensate before eventually failing. The left ventricle is a pressure-handling ventricle, built for exactly that load. That's why pulmonary hypertension causes right heart failure long before it affects the left.

Two mechanisms operate together. Viral proteins cause stiffness in the lung's interstitial tissue, which physically compresses the pulmonary blood vessels. At the same time, the immunocompromised state associated with HIV promotes smooth muscle hyperplasia within the vessel walls, narrowing the lumen from within. It's the combination of external compression and internal luminal narrowing that drives HIV-associated pulmonary hypertension.

The pulmonary valve opens against a high-pressure circuit, so when it closes, it's slammed shut by that elevated pressure — a forceful, rapid closure that produces the loud P2. It isn't the size of the valve that determines the loudness, it's the closing pressure. That's why even in conditions like tetralogy of Fallot, where pulmonary stenosis would normally produce a soft P2, elevated pulmonary arterial pressure from collateral flow can still produce a loud P2 despite the outflow obstruction.

After the first trimester, amlodipine and other calcium channel blockers are reasonably safe. For eclampsia or hypertension specifically during pregnancy, the preferred agent is a direct alpha agonist, such as prazosin.

No. Echo findings such as elevated TR jet velocity, a dilated right ventricle, or reduced TAPSE are screening signals that warrant further investigation, not diagnostic criteria on their own.

Tricuspid regurgitation has multiple causes unrelated to pulmonary hypertension, including isolated right ventricular failure, organic tricuspid valve disease, and primary TR, all of which can produce the same echo picture.

This commonly used formula for estimating pulmonary artery systolic pressure from TR velocity is unreliable and can be dangerously misleading if used as the basis for a diagnosis or treatment decision.

Right heart catheterisation is the only investigation that definitively confirms pulmonary hypertension, establishing the mean pulmonary artery pressure, measuring pulmonary vascular resistance, and determining whether the disease is precapillary or post-capillary.

Vasoreactivity testing identifies which patients are most likely to respond to medical therapy and directly guides the choice of treatment agents.